(+/-)-2-(3-((2-Cyclohexylphenoxy)methyl)pyrrolidin-1-yl)-6-methylpyrimidine-4-carboxylic Acid

ID: ALA4780787

Chembl Id: CHEMBL4780787

PubChem CID: 162662460

Max Phase: Preclinical

Molecular Formula: C23H29N3O3

Molecular Weight: 395.50

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(C(=O)O)nc(N2CCC(COc3ccccc3C3CCCCC3)C2)n1

Standard InChI:  InChI=1S/C23H29N3O3/c1-16-13-20(22(27)28)25-23(24-16)26-12-11-17(14-26)15-29-21-10-6-5-9-19(21)18-7-3-2-4-8-18/h5-6,9-10,13,17-18H,2-4,7-8,11-12,14-15H2,1H3,(H,27,28)

Standard InChI Key:  LWZDBJBYNKLOSM-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4780787

    ---

Associated Targets(Human)

RBP4 Tchem Plasma retinol-binding protein (718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TTR Tclin Transthyretin (2847 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 395.50Molecular Weight (Monoisotopic): 395.2209AlogP: 4.44#Rotatable Bonds: 6
Polar Surface Area: 75.55Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 1.55CX Basic pKa: 5.88CX LogP: 3.31CX LogD: 1.90
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.78Np Likeness Score: -0.99

References

1. Cioffi CL,Muthuraman P,Raja A,Varadi A,Racz B,Petrukhin K.  (2020)  Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.,  63  (19): [PMID:32878437] [10.1021/acs.jmedchem.0c00996]

Source